Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914). The clinical-stage biotech ...

Investors might want to bet on Q32 Bio (QTTB), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory ...

Q32 Bio (QTTB) announced that the company has dosed the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA ...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in ...

In a report released on April 16, Thomas Smith from Leerink Partners maintained a Hold rating on Q32 Bio (QTTB – Research Report). The ...

(RTTNews) - Q32 Bio Inc. (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc. (QTTB) on Tuesday reported a loss of $14.2 million in its fourth quarter. The Waltham, Massachusetts-based company said it had a loss ...

SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage ...